Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity

• Gregory N. Dietsch ,

  * E-mail: gdietsch@ventirx.com

  Affiliation VentiRx Pharmaceuticals, Seattle, WA, United States of America

  ⨯
• Hailing Lu,

  Current address: Immune Design Corporation, Seattle, WA, United States of America

  Affiliation Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, University of Washington, Seattle, WA, United States of America

  ⨯
• Yi Yang,

  Affiliation Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, University of Washington, Seattle, WA, United States of America

  ⨯
• Chihiro Morishima,

  Affiliations Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, University of Washington, Seattle, WA, United States of America, Department of Laboratory Medicine, University of Washington, Seattle, WA, United States of America

  ⨯
• Laura Q. Chow,

  Affiliation Department of Medicine, University of Washington, Seattle, WA, United States of America

  ⨯
• Mary L. Disis,

  Affiliation Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, University of Washington, Seattle, WA, United States of America

  ⨯
• Robert M. Hershberg

  Affiliation VentiRx Pharmaceuticals, Seattle, WA, United States of America

  ⨯